Editas Medicine, Inc. (EDIT) Stock Price & Analysis

Editas Medicine, Inc. (EDIT) closed at USD 2.95 on Wednesday, October 28, 2026, up 13.46% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 2.6; the Oct 28, 2026 session ranged USD 2.54–2.96 on volume of 4,407,190 shares. Market capitalization is $453.06M, with a 52-week range of USD 1.66–3.94 (NMS). Source: Nexqual, retrieved October 28, 2026 at 21:24 UTC.

Also available as compact Markdown for AI agents: nexqual.com/EDIT.md

Key facts (EDIT)

• Last four reported quarters (through Jun 30, 2026): revenue $47.0M, net income -$73.9M (-157.3% margin), free cash flow -$121M (SEC filings).
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $79K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.62 on a 1–5 scale) (13 analysts), mean target USD 6.1 (range 1–15).
• Total return with dividends: 1Y -3.0% vs S&P 500 +13.6%; 5Y -92.0% vs S&P 500 +79.8%.
• Next earnings: 2026-11-09, EPS estimate USD -0.21, revenue estimate $4.5M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (EDIT)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (EDIT)

P/S 9.6x · EV/Sales 6.3x · P/B 4.3x · FCF yield -26.61% · Earnings yield -16.32% · Net cash $156M · EV $297M

Insider sales (SEC Form 4, open-market, last ~7 months) (EDIT)

8 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (EDIT)

Consensus Hold (mean 2.62 on a 1–5 scale), 13 analysts; mean target USD 6.1 (low 1, high 15).

Rating changes, last 120 days:

Total return (dividends reinvested) (EDIT)

EDIT earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

EDIT recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

EDIT suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 9, 2026.

Companies that name EDIT in their SEC reports

EDIT analyst estimates and revisions

EDIT options: expected move

Options price a move of about ±17.3% (±$0.45) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±13% on average.

30-day implied volatility 86.3% vs 84.5% realized over the last 30 trading days. Put/call ratio (volume) 0.02. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 21:24 UTC)

Technical Analysis (EDIT)

Nexqual's technical model rates EDIT "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 28, 2026 at 21:24 UTC.

Analyst Ratings (EDIT)

Wall Street analysts rate EDIT "Hold" based on 13 analysts, with a mean price target of USD 6.1 (range USD 1–15), per Nexqual as of October 28, 2026 at 21:24 UTC.

Earnings (EDIT)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 21:24 UTC.

Financials & Fundamentals (EDIT)

Source: Nexqual, October 28, 2026 at 21:24 UTC.

Financial Health Score (EDIT)

Nexqual rates Editas Medicine, Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 21:24 UTC.

Ownership (EDIT)

Source: Nexqual, October 28, 2026 at 21:24 UTC.

Leadership (EDIT)

Editas Medicine, Inc. is led by Gilmore O'Neill, President, CEO & Director, per Nexqual as of October 28, 2026 at 21:24 UTC.

Major Backers & Investors (EDIT)

Notable institutional backers of Editas Medicine, Inc. include TCG Crossover Management, LLC, Commodore Capital Lp, RA Capital Management, L.P., according to Nexqual as of October 28, 2026 at 21:24 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 21:24 UTC.

From Editas Medicine, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)

Key Strengths & Strategy (as disclosed to the SEC)

• In December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVYTM (exagamglogene autotemcel).
• We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities.
• We believe we are the only human gene editing company with a platform that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both of these CRISPR systems, and foundational intellectual property for both of these CRISPR systems.
• We previously announced in vivo delivery to two additional cell types in humanized mice using our proprietary LNP targeting platform, demonstrating the "plug ‘n play" potential of our proprietary extrahepatic LNP platform.

Partnerships

• Examples of these licensing efforts include our non-exclusive license to Vertex for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVYTM (exagamglogene autotemcel); our non-exclusive license to Immatics of our AsCas12a technology to advance gamma-delta T cell therapies for the treatment of cancer; and our collaboration with BMS.
• In connection with the amendment and restatement in November 2019, we entered into a license agreement with BMS (such agreement, the "BMS License Agreement," and together with the BMS Collaboration Agreement, the "BMS Agreements").

Legal & Regulatory Risks (Item 1A, quoted)

• Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.
• Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
• Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, product candidates we may identify for development. We do not anticipate generating revenues from product sales for years, if ever.
• Regulatory requirements governing genetic medicines, and in particular any novel genetic medicines we may develop, have changed frequently and may continue to change in the future.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 21:24 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt